- Home
- CB vs SNY Comparison
CB vs SNY Comparison
Compare CB & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CB
- SNY
- Stock Information
- Founded
- CB 1985
- SNY 1994
- Country
- CB Switzerland
- SNY France
- Employees
- CB N/A
- SNY N/A
- Industry
- CB Property-Casualty Insurers
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- CB Finance
- SNY Health Care
- Exchange
- CB Nasdaq
- SNY Nasdaq
- Market Cap
- CB 111.9B
- SNY 116.1B
- IPO Year
- CB 1993
- SNY N/A
- Fundamental
- Price
- CB $268.19
- SNY $50.52
- Analyst Decision
- CB Buy
- SNY Buy
- Analyst Count
- CB 17
- SNY 4
- Target Price
- CB $306.82
- SNY $61.50
- AVG Volume (30 Days)
- CB 1.5M
- SNY 3.9M
- Earning Date
- CB 10-21-2025
- SNY 10-24-2025
- Dividend Yield
- CB 1.45%
- SNY 3.16%
- EPS Growth
- CB N/A
- SNY 118.56
- EPS
- CB 22.66
- SNY 8.65
- Revenue
- CB $57,486,000,000.00
- SNY $53,714,621,258.00
- Revenue This Year
- CB N/A
- SNY $1.40
- Revenue Next Year
- CB $5.67
- SNY $6.67
- P/E Ratio
- CB $11.84
- SNY $5.85
- Revenue Growth
- CB 7.11
- SNY 15.65
- 52 Week Low
- CB $252.16
- SNY $44.62
- 52 Week High
- CB $306.91
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- CB 33.83
- SNY 61.12
- Support Level
- CB $265.30
- SNY $48.54
- Resistance Level
- CB $285.62
- SNY $49.43
- Average True Range (ATR)
- CB 4.51
- SNY 0.93
- MACD
- CB -1.86
- SNY 0.21
- Stochastic Oscillator
- CB 11.47
- SNY 91.76
About CB Chubb Limited
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination made the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.